Antitumour activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2513-2518

  Ishizuka, Hiroto ^a   Watanabe, Masahiko ^a   Kubota, Tetsuro ^a   Matsuzaki, Shinjiro W ^a   Otani, Yoshihide ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Antitumour activity; Apoptosis; NCC ST 421

Indexed keywords

MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; DIMERIC LE(A) ANTIGEN, HUMAN; GANGLIOSIDE; NCC ST 421 ANTIGEN; NCC-ST-421 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; COLON TUMOR; DRUG EFFECT; ERYTHROLEUKEMIA; FEMALE; IMMUNOLOGY; MALE; MOUSE MUTANT; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; COLONIC NEOPLASMS; FEMALE; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALE; MICE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031596054     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mount PF, Sutton VR, Li W, Burgess J, McKenzie IF, Pietersz GA and Trapani JA: Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice. Cancer Res 54(23): 6160-6106, 1994.
2. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichelmaier H, Hirche H, Richlmayr R, Buggisch P, Witte J, and the German Cancer Aid 17-1A Study Group: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343: 1177-1183, 1994.
3. Reiter Y, Wright AF, Tonge DW and Pastan I: Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Int J Cancer 67(1): 113-123, 1996.
4. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM and Old LJ: Phase I/II study of iodine 125-labelled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14(6): 1787-1797, 1996.
5. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 57(11): 2181-2186, 1997.
6. Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED and Stroud MR: In vitro and in vivo antitumour effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope. Cancer Res 51 (8): 2199-2204, 1991.
7. Watanabe M, Hirohashi S, Shimosato Y, Ino Y, Yamada T, Teshima S, Sekine T and Abe O: Carbohydrate antigen defined by a monoclonal antibody raised against a gastric cancer xenograft. Jpn J Cancer Res 76: 43-52, 1985.
8. Kuzuoka M: Antitumour activity of murine monoclonal antibody NCC-ST-421. Keio Igaku 68(1): 179-188, 1991.
9. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
10. Shimoyama Y, Kubota T, Watanabe M, Ishibiki K and Abe O: Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surg Oncol 41: 12-18, 1989.
11. Suto A, Kubota T, Shimoyama Y, Ishibiki K and Abe O: MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 42: 28-32, 1989.
12. Furukawa T, Kubota T, Suto A, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K and Kitajima M: Clinical usefulness of chemosensitivity testing using the MTT assay. J Surg Oncol 48: 188-193, 1991.
13. Geran Rl, Greenberg NH, MacDonald MM, Schumacher AM and Abott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3rd ed. Cancer Chemother. Rep. (Part 3) 3: 1-103, 1972.
14. Kubota T, Nakada M, Tsuyuki K, Inada T, Asanuma F, Ishibiki K and Abe O: Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice. Jpn J Cancer Res 77(5): 502-507, 1986.
15. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
16. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of Apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
17. Stroud MR, Levery SB, Nudelman ED, Salyan ME, Towell JA, Roberts CE, Watanabe M and Hakomori S: Extended type 1 chain glycosphingolipids: dimeric Lea (III4V4Fuc2Lc6) as human tumour-associated antigen. J Biol Chem 266(13): 8439-8446, 1991.
18. Watanabe M, Kubota T, Kitajima M and Hakomori S: Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumour-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice. Cancer Immunol Immunother 37(4): 245-250, 1993.
19. Kawano Y, Watanabe M, Kubota T, Nishibori H, Kurihara N, Teramoto T and Kitajima M: A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer. Anticancer Res 17(4A): 2449-2453, 1997.
20. Wyllie AH, Kerr JFR and Curri AR: The significance of apoptosis. Int Rev Cytol 60: 251-306, 1980.
21. Kerr JFR, Winterford CM and Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
22. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumour regression by induction of apoptosis. Science 245 (4915): 301-305, 1989.
23. Vollmers HP. Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Rückle-Lanz H, Reindl L, Müller-Hermelink HK: Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antobody SC-I: first clinical and histopathological results. Oncology Reports 5: 549-552, 1998.